Assessment of the Potential Clinical and Economic Impact of Weight Loss in the Adult Population with Obesity and Associated Comorbidities in Spain

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Advances in Therapy Pub Date : 2025-01-18 DOI:10.1007/s12325-024-03094-3

María Dolores Ballesteros-Pomar, Ened Rodríguez-Urgellés, Miquel Sastre-Belío, Alberto Martín-Lorenzo, Volker Schnecke, Lluís Segú, Max Brosa, Nuria Vilarrasa

{"title":"Assessment of the Potential Clinical and Economic Impact of Weight Loss in the Adult Population with Obesity and Associated Comorbidities in Spain","authors":"María Dolores Ballesteros-Pomar, Ened Rodríguez-Urgellés, Miquel Sastre-Belío, Alberto Martín-Lorenzo, Volker Schnecke, Lluís Segú, Max Brosa, Nuria Vilarrasa","doi":"10.1007/s12325-024-03094-3","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Obesity and its complications are associated with high morbidity/mortality and a significant healthcare cost burden in Spain. It is therefore essential to know the potential clinical and economic benefits of reducing obesity. The objective of this study is to predict the decrease in rates of onset of potential complications associated with obesity and the cost savings after a weight loss of 15% over 10 years in Spain.</p><h3>Methods</h3><p>Data were combined in an adapted version of a weight loss benefit simulation model. Sources with demographic information on the Spanish population and the distribution of obesity and type 2 diabetes mellitus (T2DM) were used to obtain the data for the model. In addition, use was made of prevalence data on obesity-associated complications from a cohort of patients with obesity in the United Kingdom (UK). These data were combined by age and sex to create a Spanish synthetic cohort.</p><h3>Results</h3><p>The simulation showed that, for a cohort of 100,000 individuals with a body mass index (BMI) of 30–50 kg/m<sup>2</sup>, a weight loss of 15% is estimated to lead to relevant relative risk reductions in obstructive sleep apnoea (OSA) (− 56.4%), T2DM (− 39.2%), asthma (− 20.2%) and arterial hypertension (− 18.7%). The estimated overall savings were €105 million for a cohort of 100,000 individuals, mainly resulting from the decrease in T2DM and arterial hypertension (23% and 22% of the total savings at year 10, respectively), as well as osteoarthritis and chronic kidney disease (CKD) (16% and 13%, respectively).</p><h3>Conclusions</h3><p>Sustained weight loss could significantly reduce the burden derived from future complications associated to obesity in Spain, as well as the excess economic cost associated with its treatment.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 2","pages":"1265 - 1282"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-024-03094-3.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-03094-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Obesity and its complications are associated with high morbidity/mortality and a significant healthcare cost burden in Spain. It is therefore essential to know the potential clinical and economic benefits of reducing obesity. The objective of this study is to predict the decrease in rates of onset of potential complications associated with obesity and the cost savings after a weight loss of 15% over 10 years in Spain.

Methods

Data were combined in an adapted version of a weight loss benefit simulation model. Sources with demographic information on the Spanish population and the distribution of obesity and type 2 diabetes mellitus (T2DM) were used to obtain the data for the model. In addition, use was made of prevalence data on obesity-associated complications from a cohort of patients with obesity in the United Kingdom (UK). These data were combined by age and sex to create a Spanish synthetic cohort.

Results

The simulation showed that, for a cohort of 100,000 individuals with a body mass index (BMI) of 30–50 kg/m², a weight loss of 15% is estimated to lead to relevant relative risk reductions in obstructive sleep apnoea (OSA) (− 56.4%), T2DM (− 39.2%), asthma (− 20.2%) and arterial hypertension (− 18.7%). The estimated overall savings were €105 million for a cohort of 100,000 individuals, mainly resulting from the decrease in T2DM and arterial hypertension (23% and 22% of the total savings at year 10, respectively), as well as osteoarthritis and chronic kidney disease (CKD) (16% and 13%, respectively).

Conclusions

Sustained weight loss could significantly reduce the burden derived from future complications associated to obesity in Spain, as well as the excess economic cost associated with its treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

西班牙成人肥胖及相关合并症患者减肥的潜在临床和经济影响评估

在西班牙，肥胖及其并发症与高发病率/死亡率和显著的医疗成本负担相关。因此，了解减少肥胖的潜在临床和经济效益是至关重要的。本研究的目的是预测西班牙10年内体重减轻15%后与肥胖相关的潜在并发症发生率的下降和成本节约。方法：将数据合并到减肥效益模拟模型的改编版本中。西班牙人口统计信息来源以及肥胖和2型糖尿病（T2DM）的分布被用来获得模型的数据。此外，本研究还利用了来自英国一组肥胖患者的肥胖相关并发症的流行数据。这些数据按年龄和性别组合在一起，形成了一个西班牙合成队列。结果：模拟显示，对于10万名体重指数（BMI）为30-50 kg/m2的个体，体重减轻15%估计会导致阻塞性睡眠呼吸暂停（OSA）（- 56.4%）、T2DM（- 39.2%）、哮喘（- 20.2%）和动脉高血压（- 18.7%）的相关相对风险降低。在100,000人的队列中，估计总体节省1.05亿欧元，主要是由于T2DM和动脉高血压的减少（分别占第10年总节省的23%和22%），以及骨关节炎和慢性肾脏疾病（CKD）的减少（分别占16%和13%）。结论：在西班牙，持续减肥可以显著减少未来肥胖并发症带来的负担，以及与肥胖治疗相关的额外经济成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.